Altimmune

ALTNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$663.305 M

$3.41 +4.28%

Close of 22 Sept 2026

Revenue

$41.0K

#3610 by revenue

Earnings

-$88.1M

Loss-making

Shares outstanding

194,517,701

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#187Sagimet BiosciencesSGMT$683.0M
#188NeurogeneNGNE$672.4M
#189AltimmuneALT$663.3M
#190Shattuck LabsSTTK$652.4M
#191Monopar TherapeuticsMNPR$648.6M

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Altimmune, worth $44.3K. Grants and option exercises are excluded.

Jerome Benedict DursoPresident and CEO$44.3K
15,000 shares at $2.95 on 13 Aug 2026 · filed 13 Aug 2026

What if Altimmune were worth as much as…

Open the what-if tool →

Gold $30.2T

$155,430.43

Per share 45,581× higher

Bitcoin $1.74T

$8,953.71

Per share 2,626× higher

Nvidia $5.52T

$28,356.12

Per share 8,316× higher

Or at a round number

$1.00B $2.00B $5.00B $10.0B

Where these numbers come from

Share counts and financials for Altimmune are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.